Form D · Pharmaceuticals

Transposon Therapeutics, Inc.

San Diego, CA · CIK 0001810705

Offering snapshot reported Jul 15, 2024 · SEC filing

Reported sold
$4.68M
Offering amount: $20M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 10, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 15, 2024Initial$4,679,395No comparison8SEC filing
Jan 12, 2023Amendment$5,005,000$5,005,000vs Dec 29, 20228SEC filing
Dec 29, 2022Initial$0No comparison8SEC filing
Dec 9, 2020Initial$45,187,328No comparison10SEC filing
May 6, 2020Initial$4,250,000No comparison4SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-518803

Source: Form D, filed Jul 15, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Brent Ahrens Director
William Harrington, Md, Mba Director
Daniel Hetu, Md, Mba Director
Keith A. Katkin Director
John Pacifico Director
Dennis Podlesak Director, Executive
Lynne R. Rollins Executive
Brian Taylor Slingsby, Md, Phd, Mph Director
Eckard Weber, Md Director, Executive
Eckard Weber, M.D. Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
4660 La Jolla Village Drive Suites 100 & 200
San Diego, CA, 92112